Safety overview of new disease-modifying antirheumatic drugs

Research output: Contribution to journalReview article

41 Citations (Scopus)

Abstract

The use of novel DMARDs (leflunomide, anakinra, TNF inhibitors) has produced newfound levels of patient satisfaction. The toxicities detailed herein are often mild to moderate, often resolve or are well tolerated, and seldom warrant discontinuation of the drug. Serious and potentially life-threatening adverse events are rare, even in the postmarketing era. Clinicians should be mindful of these rare adverse events (eg, tuberculosis or lymphoma) and should counsel patients appropriately based on their concerns and quality of life. Because many of these serious toxicities occur at rates of 1 or fewer cases per 1000 patient years of use, it appears that proper patient selection and prevention measures are needed to further limit this risk.

Original languageEnglish (US)
Pages (from-to)237-255
Number of pages19
JournalRheumatic Disease Clinics of North America
Volume30
Issue number2
DOIs
StatePublished - May 1 2004
Externally publishedYes

Fingerprint

Antirheumatic Agents
leflunomide
Interleukin 1 Receptor Antagonist Protein
Safety
Patient Satisfaction
Patient Selection
Lymphoma
Tuberculosis
Quality of Life
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Rheumatology

Cite this

Safety overview of new disease-modifying antirheumatic drugs. / Cush, John J.

In: Rheumatic Disease Clinics of North America, Vol. 30, No. 2, 01.05.2004, p. 237-255.

Research output: Contribution to journalReview article

@article{dd6dc332da0d43e68f908d1a5c24bc90,
title = "Safety overview of new disease-modifying antirheumatic drugs",
abstract = "The use of novel DMARDs (leflunomide, anakinra, TNF inhibitors) has produced newfound levels of patient satisfaction. The toxicities detailed herein are often mild to moderate, often resolve or are well tolerated, and seldom warrant discontinuation of the drug. Serious and potentially life-threatening adverse events are rare, even in the postmarketing era. Clinicians should be mindful of these rare adverse events (eg, tuberculosis or lymphoma) and should counsel patients appropriately based on their concerns and quality of life. Because many of these serious toxicities occur at rates of 1 or fewer cases per 1000 patient years of use, it appears that proper patient selection and prevention measures are needed to further limit this risk.",
author = "Cush, {John J.}",
year = "2004",
month = "5",
day = "1",
doi = "10.1016/j.rdc.2004.02.003",
language = "English (US)",
volume = "30",
pages = "237--255",
journal = "Rheumatic Disease Clinics of North America",
issn = "0889-857X",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Safety overview of new disease-modifying antirheumatic drugs

AU - Cush, John J.

PY - 2004/5/1

Y1 - 2004/5/1

N2 - The use of novel DMARDs (leflunomide, anakinra, TNF inhibitors) has produced newfound levels of patient satisfaction. The toxicities detailed herein are often mild to moderate, often resolve or are well tolerated, and seldom warrant discontinuation of the drug. Serious and potentially life-threatening adverse events are rare, even in the postmarketing era. Clinicians should be mindful of these rare adverse events (eg, tuberculosis or lymphoma) and should counsel patients appropriately based on their concerns and quality of life. Because many of these serious toxicities occur at rates of 1 or fewer cases per 1000 patient years of use, it appears that proper patient selection and prevention measures are needed to further limit this risk.

AB - The use of novel DMARDs (leflunomide, anakinra, TNF inhibitors) has produced newfound levels of patient satisfaction. The toxicities detailed herein are often mild to moderate, often resolve or are well tolerated, and seldom warrant discontinuation of the drug. Serious and potentially life-threatening adverse events are rare, even in the postmarketing era. Clinicians should be mindful of these rare adverse events (eg, tuberculosis or lymphoma) and should counsel patients appropriately based on their concerns and quality of life. Because many of these serious toxicities occur at rates of 1 or fewer cases per 1000 patient years of use, it appears that proper patient selection and prevention measures are needed to further limit this risk.

UR - http://www.scopus.com/inward/record.url?scp=2542485453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542485453&partnerID=8YFLogxK

U2 - 10.1016/j.rdc.2004.02.003

DO - 10.1016/j.rdc.2004.02.003

M3 - Review article

C2 - 15172038

AN - SCOPUS:2542485453

VL - 30

SP - 237

EP - 255

JO - Rheumatic Disease Clinics of North America

JF - Rheumatic Disease Clinics of North America

SN - 0889-857X

IS - 2

ER -